What is Ublituximab?
Ublituximab is utilized to treat people who suffer from the relapsing form of MS, which includes the clinically isolated syndrome, relapsing-remitting disease, and chronic secondary progressive diseases. Ublituximab can also be employed for other purposes that are not covered in this guideline.
Side effects of Ublituximab
See a doctor immediately. Get medical attention immediately if you notice symptoms that indicate an allergic reaction, such as symptoms of hives, difficulty breathing, and swelling of your lips, face, and tongue. Certain side effects can be experienced during or following the injection. Contact your doctor when you feel dizzy, nauseated, lightheaded, and sweaty, or when you experience headaches, chest tightness, back discomfort, breathing problems, or a swelling of your face.
If you've suffered from hepatitis B, you may experience it again or worsen. It's possible to require liver function tests when you are using ublituximab and for some time after quitting. Ublituximab could cause a brain infection, which can cause disabilities or even death. Consult your physician. If you experience difficulties with speech, thinking, vision, or movement, These signs can become more severe quickly.
Ublituximab could cause serious adverse reactions. Consult your physician immediately in the event that you experience:
- Burning and pain during urination; or
- Symptoms of infection: signs of infection: fever, chills sore throat and body aches. Unusual fatigue or loss of appetite. Bleeding or bruising.
Common adverse reactions to ublituximab can be:
- Dizziness dizziness, nausea, fainting, itchy, sweaty chest tightness, headache, back pain, difficulty breathing, or swelling of your face;
- Sores that are cold in your mouth: blisters, skin sores, itching, burning pain, or tingling sensations in your lower back;
- Symptoms of the cold, like congestion, sneezing, and a sore throat,
- Discomfort in your hands and feet;
- Sleep problems (insomnia); or
This isn't a complete list of all the side effects. Others could happen. Consult your physician to seek medical advice on the effects. You can report adverse reactions to the FDA at 1-800-FDA-1088.
Warnings
Certain side effects can be experienced during or following the injection. Inform your doctor when you feel dizzy, nauseated, lightheaded, or sweaty. or if you experience headaches, back pain, chest tightness, trouble breathing, or swelling of your face.
If you've been a victim of hepatitis B, it is possible that it will return or become worse. Tell your doctor if you're feeling unwell and are experiencing upper stomach pain on the right side, vomiting, a lack of appetite, or a yellowing of your eyes or skin.
Ublituximab could cause a brain injury, which can cause disability or even death. Consult your physician when you are experiencing problems with your thinking, speech, or vision, as well as muscle movement. These signs can become more severe quickly.
Prior to use this drug
It is not recommended to use ublituximab if you have an allergy to this medication or suffer from
- Hepatitis b is an active b infection.
Inform your doctor if you have had or have ever experienced:
- An ongoing or chronic infection;
- Hepatitis b and are carriers of the hepatitis b virus.
- Had a recent vaccination, had a scheduled vaccine, or
- If you are planning to use medicines that can affect your immunity,
It may be necessary to conduct a pregnancy test that is negative prior to each dose of Ublituximab.
Could harm the unborn baby. Do not take this medication during pregnancy. Make sure you use an effective birth control method while taking Ublituximab and for at least six months following the last dose. Consult your physician if you fall pregnant.
Check with your doctor to get advice on whether it is safe to breastfeed while taking Ublituximab.
How to take Ublituximab?
Follow the directions on your prescription label, and review all instructions or medication guides. Ublituximab is injectable into veins by a doctor. You might also be prescribed other medicines to prevent severe side effects or allergic reactions. Continue taking these medications for as long as your physician prescribes. The blood of your patient will be examined prior to and during treatment with Ublituximab.
Details on dosage
Usual Adult Dose for Multiple Sclerosis:
First Infusion:
150 mg IV administered over a minimum of 4 hours
Infuse at a dose of 10 mL per hour for the first 30 minutes.
Increase the flow to 20 milliliters per hour in the following 30 minutes.
Increase the flow to 35 mL/hour during the next hour.
Increase the flow to 100 mL/hour for the remaining two hours.
2nd Infusion (2 weeks following the first infusion):
500 mg IV administered over at least one hour
Start the infusion with a dose of 100 mL/hour during the initial 30 minutes.
Increase the flow rate to 400 milliliters per hour during the next 30 minutes.
Following infusions (24 weeks after the initial infusion):
500 mg IV once every 24 weeks for at least one hour
Start the infusion with a dose of 100 mL per hour within the first thirty minutes.
Increase the flow rate to 400 milliliters every hour over the next 30 minutes.
Comments:
Premedicate with a corticosteroid 30 minutes prior to every infusion of this medication, an antihistamine for 30–60 minutes prior to every infusion of this medication, and an additional antipyretic medication if necessary to decrease the severity and frequency of reactions to the infusion.
Monitor for reactions to infusions during and for a minimum of an hour after the initial two infusions. Depending on the doctor's discretion, continue monitoring following the next infusion unless an infusion reaction or hypersensitivity was observed during the present or previous infusion.
Check for pregnancy status in females with childbearing potential prior to every infusion.
Use: In the treatment of relapsing forms of MS in adults.
What happens if I miss the dose?
Consult your physician for treatment. If you do not make an appointment to receive your ublituximab treatment,
What happens if I overdose?
In a medical environment, an overdose could be immediately treated.
What should be avoided?
Do not receive a "live" vaccine while you are receiving treatment for Ublituximab for at least 4 weeks prior to the treatment. Live vaccines comprise measles, mumps, and rubella (MMR), as well as the typhoid virus, rotavirus, yellow fever varicella (chickenpox), and shingles. Beware of receiving a "non-live" vaccine for at least two weeks prior to the treatment with Ublituximab.
Interaction with other drugs
Inform your doctor about all other medications, including:
- Medicines that can weaken your immune system, such as cancer medication, steroids, and medications that hinder organ donation
This list isn't complete. Other drugs can interact with the ublituximab drug, including prescription and over-the-counter medicines, vitamins, and herbal supplements. There are many possible interactions between drugs that are included here.
